drugset / Trial / NCT04050462
Nivolumab Combined With BMS-986253 in HCC Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.
Timeline
- Start
- 2019-09-12
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Outcome
Outcome not reported
Stopped (Enrollment): “Study was terminated early by the drug sponsor due to slow accrual and a change in the company's drug development priorities”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADAKITUG | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Cabiralizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |